Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
2.
J Clin Pathol ; 62(11): 1021-5, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19861561

ABSTRACT

BACKGROUND: Venous invasion (VI) is an important prognostic factor in colorectal cancer; it is positively associated with visceral metastases and may affect the decision to treat with adjuvant therapy. AIMS: To evaluate whether an elastic tissue (Movat) stain facilitates identification of VI, the number of Movat-stained blocks needed to detect VI, and whether VI identified with a Movat stain is prognostically equivalent to VI identified on H&E-stained slides. METHODS: H&E-stained sections from colorectal carcinomas from the year 2000 (n = 92) were examined for VI and compared to Movat-stained slides. Clinical charts were reviewed to compare rates of metastases in VI-positive versus VI-negative patients. RESULTS: With the Movat stain, VI was identified in 44% of cases previously categorised as negative (p<0.001) on review of H&E slides alone. One Movat-stained section was often sufficient to identify VI, with a statistically significant benefit to performing multiple stains if necessary. In H&E sections, two clues helped identify VI: the "unaccompanied artery" sign, where large arteries were seen without an accompanying vein; and the "protruding tongue" sign, where smooth tongues of tumour extended into pericolic/rectal fat. Metastases were present in 61% of cases positive for VI compared to 35% in VI-negative cases (p = 0.03). 45% of cases positive for intramural VI only developed metastases (p = 0.39), while 65% of cases positive for extramural VI only developed metastases (p = 0.03). CONCLUSIONS: Pathologists should look for morphological clues of VI in H&E stained sections; when VI is not apparent, an elastic tissue stain on all tumour blocks significantly improves identification of VI. Morphological clues include the "unaccompanied artery" and "protruding tongue" signs.


Subject(s)
Adenocarcinoma/pathology , Blood Vessels/pathology , Colorectal Neoplasms/pathology , Adenocarcinoma/secondary , Adenocarcinoma/therapy , Chemotherapy, Adjuvant , Colorectal Neoplasms/therapy , Elastic Tissue/pathology , Humans , Neoplasm Invasiveness , Neoplasm Staging , Prognosis , Radiotherapy, Adjuvant , Retrospective Studies , Specimen Handling/methods , Staining and Labeling/methods , Treatment Outcome
3.
Biochem Biophys Res Commun ; 257(1): 129-38, 1999 Apr 02.
Article in English | MEDLINE | ID: mdl-10092522

ABSTRACT

Hematopoietic cell kinase (Hck) is a member of the Src-family of protein tyrosine kinases. We have found that upon enzymatic activation of Hck by the heavy metal mercuric chloride, there was a rapid increase in the levels of tyrosine phosphorylation of several proteins including the proto-oncogene p120(Cbl). Fibroblasts that are transformed with an activated allele of Hck exhibit constitutive Cbl phosphorylation. Upon Fcgamma receptor activation, a more physiologically relevant extracellular signal, Cbl is tyrosine phosphorylated and the Src-family selective inhibitor, PP1, can prevent this phosphorylation on Cbl. Hck phosphorylates Cbl in vitro and the interaction between Cbl and Hck is direct, requiring Hck's unique, SH3 and SH2 domains for optimal binding. Using a novel estrogen-regulated chimera of Hck we have shown a hormone-dependent association between Hck and Cbl in murine fibroblasts. This work suggests that Cbl serves as a key mediator of Hck induced signalling in hematopoietic cells.


Subject(s)
Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins/metabolism , Ubiquitin-Protein Ligases , 3T3 Cells , Alleles , Animals , Cell Line, Transformed , Enzyme Activation/drug effects , Estradiol/pharmacology , Humans , Mercuric Chloride/pharmacology , Mice , Phosphorylation/drug effects , Phosphotyrosine/metabolism , Precipitin Tests , Protein Binding , Protein-Tyrosine Kinases/genetics , Proto-Oncogene Mas , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins c-cbl , Proto-Oncogene Proteins c-hck , Pyrazoles/pharmacology , Pyrimidines/pharmacology , Receptor Aggregation , Receptors, IgG/antagonists & inhibitors , Receptors, IgG/metabolism , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/metabolism , Transfection , Tumor Cells, Cultured , src Homology Domains/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...